Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Onyvax-P vaccine: Phase IIa

Interim results from an open-label, U.K. Phase IIa trial showed that 20 of 26 evaluable patients

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE